Cancer epidemiology · 2026
Prevalence of Veteran-reported treatment barriers from the breast and gynecologic oncology system of excellence.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Smith Imari Z, Zullig Leah L, Berkowitz Theodore S, Cummin Graham, Weidenbacher Hollis J, Moss Haley, Colonna Sarah, Kelley Michael J, Patil Vikas, Halwani Ahmad S, Shepherd-Banigan Megan
Аннотация
BACKGROUND: There are many barriers to cancer care for patients with breast and gynecologic cancers. While much is known about barriers to breast and gynecologic cancer in the civilian population, less is known about barriers reported by Veterans. We address this knowledge gap by using data from the Breast and Gynecologic Oncology System of Excellence (BGSoE) to identify key treatment barriers reported by Veterans diagnosed with gynecologic and breast cancers.
METHODS: We employ cross-sectional data from the BGSoE dashboard to identify Veterans who were diagnosed with breast or gynecologic cancers from January 1, 2021 to March 15, 2024 and receive VA health care. We computed descriptive statistics for the barriers to treatment after breast and gynecologic cancer diagnosis.
FINDINGS: Over half (56%) of Veterans reported one or more barriers to cancer treatment. There were no significant racial, sex, or age differences between Veterans who indicated any treatment barriers and those who did not. The most indicated barriers were related to care coordination (37%), logistical factors (29%), and psychosocial and behavioral factors (16%).
CONCLUSIONS: Our findings among Veterans with breast and gynecologic cancers broadly echo the trends observed in studies of civilians. However, while Veterans do not report barriers related to medication costs and lacking insurance coverage, they do report barriers related to "eligibility problems" and "confusing financial paperwork." These findings speak to the nuances of treatment barriers among Veterans that need to be addressed to improve VA breast and gynecologic cancer treatment outcomes.
METHODS: We employ cross-sectional data from the BGSoE dashboard to identify Veterans who were diagnosed with breast or gynecologic cancers from January 1, 2021 to March 15, 2024 and receive VA health care. We computed descriptive statistics for the barriers to treatment after breast and gynecologic cancer diagnosis.
FINDINGS: Over half (56%) of Veterans reported one or more barriers to cancer treatment. There were no significant racial, sex, or age differences between Veterans who indicated any treatment barriers and those who did not. The most indicated barriers were related to care coordination (37%), logistical factors (29%), and psychosocial and behavioral factors (16%).
CONCLUSIONS: Our findings among Veterans with breast and gynecologic cancers broadly echo the trends observed in studies of civilians. However, while Veterans do not report barriers related to medication costs and lacking insurance coverage, they do report barriers related to "eligibility problems" and "confusing financial paperwork." These findings speak to the nuances of treatment barriers among Veterans that need to be addressed to improve VA breast and gynecologic cancer treatment outcomes.